Cargando…

The Value of Sentinel Lymph Node Mapping for the Staging of Node-Negative Colon Cancer: Propensity Score and Mediation Analyses

OBJECTIVES: Mediation analysis to assess the protective impact of sentinel lymph node (SLN) mapping on prognosis and survival of patients with colon cancer through a more precise evaluation of the lymph node (LN) status. BACKGROUND: Up to 20% of patients with node-negative colon cancer develop disea...

Descripción completa

Detalles Bibliográficos
Autores principales: Weixler, Benjamin, Ramser, Michaela, Warschkow, Rene, Viehl, Carsten T., Vaughan-Shaw, Peter G., Zettl, Andreas, Kettelhack, Christoph, Zuber, Markus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health, Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10455289/
https://www.ncbi.nlm.nih.gov/pubmed/37635823
http://dx.doi.org/10.1097/AS9.0000000000000084
_version_ 1785096416645873664
author Weixler, Benjamin
Ramser, Michaela
Warschkow, Rene
Viehl, Carsten T.
Vaughan-Shaw, Peter G.
Zettl, Andreas
Kettelhack, Christoph
Zuber, Markus
author_facet Weixler, Benjamin
Ramser, Michaela
Warschkow, Rene
Viehl, Carsten T.
Vaughan-Shaw, Peter G.
Zettl, Andreas
Kettelhack, Christoph
Zuber, Markus
author_sort Weixler, Benjamin
collection PubMed
description OBJECTIVES: Mediation analysis to assess the protective impact of sentinel lymph node (SLN) mapping on prognosis and survival of patients with colon cancer through a more precise evaluation of the lymph node (LN) status. BACKGROUND: Up to 20% of patients with node-negative colon cancer develop disease recurrence. Conventional histopathological LN examination may be limited in describing the real metastatic burden of LN. METHODS: Data of 312 patients with stage I & II colon cancer was collected prospectively. Patients were either staged using intraoperative SLN mapping with multilevel sectioning and immunohistochemical staining of the SLN or conventional techniques. The value of the SLN mapping for the detection of truly node-negative patients was assessed using Cox regression and mediation analysis. RESULTS: SLN mapping was performed in 143 patients. Disease recurrence was observed in 13 (9.1%) patients staged with SLN mapping and in 27 (16%) staged conventionally. Five-year overall survival (OS) rate was 82.7% (95% confidence interval [CI], 76.5–89.4%) with SLN mapping compared with 65.8% (95% CI, 58.8–73.7%). Five-year cancer-specific survival (CSS) was 95.1% (95% CI, 91.3–99.0%) with SLN mapping compared with 92.5% (95% CI, 88.0–97.2%). Node-negative staging with SLN mapping was associated with significantly better OS (hazard ratio [HR], 0.64; 95% CI, 0.56–0.72; P < 0.001) and CSS (HR, 0.49; 95% CI, 0.39–0.61; P < 0.001) in multivariate analysis. Mediation analysis confirmed a direct protective effect of SLN mapping on OS (HR, 0.78; 95% CI, 0.52–0.96; P < 0.01) and disease-free survival (DFS) (HR, 0.75; 95% CI, 0.48–0.89; P < 0.01). CONCLUSIONS: Staging performed by SLN mapping with multilevel sectioning provides more accurate results than conventional staging. The observed clinically relevant and statistically significant benefit in OS and DFS is explained by a more accurate detection of positive LN by SLN mapping.
format Online
Article
Text
id pubmed-10455289
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Wolters Kluwer Health, Inc.
record_format MEDLINE/PubMed
spelling pubmed-104552892023-08-26 The Value of Sentinel Lymph Node Mapping for the Staging of Node-Negative Colon Cancer: Propensity Score and Mediation Analyses Weixler, Benjamin Ramser, Michaela Warschkow, Rene Viehl, Carsten T. Vaughan-Shaw, Peter G. Zettl, Andreas Kettelhack, Christoph Zuber, Markus Ann Surg Open Original Study OBJECTIVES: Mediation analysis to assess the protective impact of sentinel lymph node (SLN) mapping on prognosis and survival of patients with colon cancer through a more precise evaluation of the lymph node (LN) status. BACKGROUND: Up to 20% of patients with node-negative colon cancer develop disease recurrence. Conventional histopathological LN examination may be limited in describing the real metastatic burden of LN. METHODS: Data of 312 patients with stage I & II colon cancer was collected prospectively. Patients were either staged using intraoperative SLN mapping with multilevel sectioning and immunohistochemical staining of the SLN or conventional techniques. The value of the SLN mapping for the detection of truly node-negative patients was assessed using Cox regression and mediation analysis. RESULTS: SLN mapping was performed in 143 patients. Disease recurrence was observed in 13 (9.1%) patients staged with SLN mapping and in 27 (16%) staged conventionally. Five-year overall survival (OS) rate was 82.7% (95% confidence interval [CI], 76.5–89.4%) with SLN mapping compared with 65.8% (95% CI, 58.8–73.7%). Five-year cancer-specific survival (CSS) was 95.1% (95% CI, 91.3–99.0%) with SLN mapping compared with 92.5% (95% CI, 88.0–97.2%). Node-negative staging with SLN mapping was associated with significantly better OS (hazard ratio [HR], 0.64; 95% CI, 0.56–0.72; P < 0.001) and CSS (HR, 0.49; 95% CI, 0.39–0.61; P < 0.001) in multivariate analysis. Mediation analysis confirmed a direct protective effect of SLN mapping on OS (HR, 0.78; 95% CI, 0.52–0.96; P < 0.01) and disease-free survival (DFS) (HR, 0.75; 95% CI, 0.48–0.89; P < 0.01). CONCLUSIONS: Staging performed by SLN mapping with multilevel sectioning provides more accurate results than conventional staging. The observed clinically relevant and statistically significant benefit in OS and DFS is explained by a more accurate detection of positive LN by SLN mapping. Wolters Kluwer Health, Inc. 2021-07-26 /pmc/articles/PMC10455289/ /pubmed/37635823 http://dx.doi.org/10.1097/AS9.0000000000000084 Text en Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
spellingShingle Original Study
Weixler, Benjamin
Ramser, Michaela
Warschkow, Rene
Viehl, Carsten T.
Vaughan-Shaw, Peter G.
Zettl, Andreas
Kettelhack, Christoph
Zuber, Markus
The Value of Sentinel Lymph Node Mapping for the Staging of Node-Negative Colon Cancer: Propensity Score and Mediation Analyses
title The Value of Sentinel Lymph Node Mapping for the Staging of Node-Negative Colon Cancer: Propensity Score and Mediation Analyses
title_full The Value of Sentinel Lymph Node Mapping for the Staging of Node-Negative Colon Cancer: Propensity Score and Mediation Analyses
title_fullStr The Value of Sentinel Lymph Node Mapping for the Staging of Node-Negative Colon Cancer: Propensity Score and Mediation Analyses
title_full_unstemmed The Value of Sentinel Lymph Node Mapping for the Staging of Node-Negative Colon Cancer: Propensity Score and Mediation Analyses
title_short The Value of Sentinel Lymph Node Mapping for the Staging of Node-Negative Colon Cancer: Propensity Score and Mediation Analyses
title_sort value of sentinel lymph node mapping for the staging of node-negative colon cancer: propensity score and mediation analyses
topic Original Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10455289/
https://www.ncbi.nlm.nih.gov/pubmed/37635823
http://dx.doi.org/10.1097/AS9.0000000000000084
work_keys_str_mv AT weixlerbenjamin thevalueofsentinellymphnodemappingforthestagingofnodenegativecoloncancerpropensityscoreandmediationanalyses
AT ramsermichaela thevalueofsentinellymphnodemappingforthestagingofnodenegativecoloncancerpropensityscoreandmediationanalyses
AT warschkowrene thevalueofsentinellymphnodemappingforthestagingofnodenegativecoloncancerpropensityscoreandmediationanalyses
AT viehlcarstent thevalueofsentinellymphnodemappingforthestagingofnodenegativecoloncancerpropensityscoreandmediationanalyses
AT vaughanshawpeterg thevalueofsentinellymphnodemappingforthestagingofnodenegativecoloncancerpropensityscoreandmediationanalyses
AT zettlandreas thevalueofsentinellymphnodemappingforthestagingofnodenegativecoloncancerpropensityscoreandmediationanalyses
AT kettelhackchristoph thevalueofsentinellymphnodemappingforthestagingofnodenegativecoloncancerpropensityscoreandmediationanalyses
AT zubermarkus thevalueofsentinellymphnodemappingforthestagingofnodenegativecoloncancerpropensityscoreandmediationanalyses
AT weixlerbenjamin valueofsentinellymphnodemappingforthestagingofnodenegativecoloncancerpropensityscoreandmediationanalyses
AT ramsermichaela valueofsentinellymphnodemappingforthestagingofnodenegativecoloncancerpropensityscoreandmediationanalyses
AT warschkowrene valueofsentinellymphnodemappingforthestagingofnodenegativecoloncancerpropensityscoreandmediationanalyses
AT viehlcarstent valueofsentinellymphnodemappingforthestagingofnodenegativecoloncancerpropensityscoreandmediationanalyses
AT vaughanshawpeterg valueofsentinellymphnodemappingforthestagingofnodenegativecoloncancerpropensityscoreandmediationanalyses
AT zettlandreas valueofsentinellymphnodemappingforthestagingofnodenegativecoloncancerpropensityscoreandmediationanalyses
AT kettelhackchristoph valueofsentinellymphnodemappingforthestagingofnodenegativecoloncancerpropensityscoreandmediationanalyses
AT zubermarkus valueofsentinellymphnodemappingforthestagingofnodenegativecoloncancerpropensityscoreandmediationanalyses